Cilnical significance of serum human kallikrein 11 in patients with ovarian cancer
10.3760/cma.j.issn.1008-6706.2011.15.002
- VernacularTitle:卵巢癌患者血清组织激肽释放酶11检测及意义
- Author:
Shijun SONG
;
Xuan ZHANG
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Tissue kallikrein
- From:
Chinese Journal of Primary Medicine and Pharmacy
2011;18(15):2020-2021
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the diagnostic and prognostic significance of serum human kallikrein11 ( KLK11 ) in patients with ovarian cancer. MethodsThe level of serum KLK11 was determined by enzyme-linked immunoassay(ELISA) for 30 patients with ovarian cancer, 26 patients with benign gynecologic processes and 32 healthy subjects,and the KLK11 value beyond the upper-limit of 95％ credibility interval( 95％ CI) based on the health controls was used as the positive value. The positive rate of KLK11 was compared among the three groups.ResultsThe positive rate of KLK11 in patients with ovarian cancer was significantly higher than those in patients with benign gynecologic processes or in healthy subjects[(73.3％) and(7.7％ ) or(6.3％ ) ,all P ＜0.01 )] ,and there was no significant difference between ovarian benign tumor group and the healthy control group ( P ＞ 0.05 ).ConclusionThe serum KLK11 should be a novel tumor marker in the clinical diagnosis of ovarian cancer.
